JP2014509595A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509595A5
JP2014509595A5 JP2013558234A JP2013558234A JP2014509595A5 JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5 JP 2013558234 A JP2013558234 A JP 2013558234A JP 2013558234 A JP2013558234 A JP 2013558234A JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5
Authority
JP
Japan
Prior art keywords
cancer
seq
immunotherapeutic composition
brachyury
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013558234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509595A (ja
JP6068368B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/029636 external-priority patent/WO2012125998A1/en
Publication of JP2014509595A publication Critical patent/JP2014509595A/ja
Publication of JP2014509595A5 publication Critical patent/JP2014509595A5/ja
Application granted granted Critical
Publication of JP6068368B2 publication Critical patent/JP6068368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013558234A 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物 Active JP6068368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17
US61/453,656 2011-03-17
PCT/US2012/029636 WO2012125998A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016249307A Division JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物

Publications (3)

Publication Number Publication Date
JP2014509595A JP2014509595A (ja) 2014-04-21
JP2014509595A5 true JP2014509595A5 (enExample) 2015-04-30
JP6068368B2 JP6068368B2 (ja) 2017-01-25

Family

ID=46831122

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013558234A Active JP6068368B2 (ja) 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物
JP2016249307A Active JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016249307A Active JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Country Status (19)

Country Link
US (5) US9198941B2 (enExample)
EP (2) EP2685995B1 (enExample)
JP (4) JP6068368B2 (enExample)
KR (1) KR102046449B1 (enExample)
CN (1) CN103648513B (enExample)
AU (3) AU2012228937B2 (enExample)
BR (1) BR112013023456B1 (enExample)
CA (1) CA2835475C (enExample)
DK (1) DK2685995T3 (enExample)
ES (1) ES2627979T3 (enExample)
HK (1) HK1245649A1 (enExample)
HU (1) HUE033491T2 (enExample)
IL (1) IL228421B (enExample)
MX (1) MX350661B (enExample)
PL (1) PL2685995T3 (enExample)
PT (1) PT2685995T (enExample)
RU (2) RU2690180C2 (enExample)
SG (2) SG193396A1 (enExample)
WO (1) WO2012125998A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン,インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
MX374829B (es) * 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
TWI748957B (zh) * 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型(Brachyury)免疫治療組合物
JP7048482B2 (ja) 2015-08-03 2022-04-05 アメリカ合衆国 Brachyury欠失変異体、Brachyury欠失変異体をコードする非酵母ベクター、及びそれらの使用
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル,インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
US20190125852A1 (en) * 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
WO2018094190A2 (en) * 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
US11510982B2 (en) * 2017-08-15 2022-11-29 Nantcell, Inc. HaNK cetuximab combinations and methods
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
EP4489774A4 (en) * 2022-03-08 2026-04-29 Immunitybio Inc YEAST-BASED VACCINE INJECTED INTRATUMORALLY

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン,インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
CN101687030B (zh) 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
WO2008115610A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン,インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途

Similar Documents

Publication Publication Date Title
RU2013146324A (ru) Иммунотерапевтические композиции на основе дрожжей с brachyury
Zhang et al. Personalized cancer vaccines: Targeting the cancer mutanome
Vacchelli et al. Trial watch: Peptide vaccines in cancer therapy
JP2012524075A5 (enExample)
Kumai et al. Cancer immunotherapy: moving forward with peptide T cell vaccines
RU2014109741A (ru) Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
IL294183B2 (en) shared neoantigens
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
CN110621334A (zh) 个性化免疫原性肽鉴定平台
JP2018501243A (ja) 組み換え型リステリア菌株を用いた併用療法
JP2019512020A5 (enExample)
Baratta Glioblastoma is' hot'for personalized vaccines
JP2018522041A5 (enExample)
EP4357356A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
JP2020511139A5 (enExample)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Chen et al. The current therapeutic cancer vaccines landscape in non‐small cell lung cancer
Izzi et al. Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains
Suzuki et al. Current status of vaccine immunotherapy for gastrointestinal cancers
JP2020507332A5 (enExample)
Horwich et al. 1000 Organ conservation in bladder cancer
Chu et al. Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy
Mohapatra et al. Cancer vaccines: types, mechanisms, and recent developments
Sasada et al. A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies
Alanazi et al. Advances in Prostate Cancer Immunotherapy: Current Options and Emerging Novel Approaches